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Abstract
The mainstay treatment for schizophrenia is antipsychotic drugs (APDs), which are mostly effective against
the positive symptoms (e.g. hallucinations), but provide minimal benefits for the negative symptoms (e.g.
social withdrawal) and cognitive deficits. We have recently shown that treatment with the non-intoxicating
phytocannabinoid, cannabidiol (CBD), can improve cognition and social interaction deficits in a maternal
immune activation (MIA) model relevant to the aetiology of schizophrenia, however, the mechanisms
underlying this effect are unknown. An imbalance in the main excitatory (glutamate) and inhibitory (GABA)
neurotransmitter systems in the brain plays a role in the pathophysiology of schizophrenia. Therefore, the
endocannabinoid system could represent a therapeutic target for schizophrenia as a regulator of glutamate and
GABA release via the CB1 receptor (CB1R). This study investigated the effects of chronic CBD treatment on
markers of glutamatergic, GABAergic and endocannabinoid signalling in brain regions implicated in social
behaviour and cognitive function, including the prefrontal cortex (PFC) and hippocampus (HPC). Time-
mated pregnant Sprague-Dawley rats (n = 16) were administered poly I:C (4 mg/kg, i.v.) or saline (control)
on gestational day 15. Male offspring were injected with CBD (10 mg/kg, i.p.) or vehicle twice daily from
postnatal day 56 for 3 weeks. The prefrontal cortex (PFC) and hippocampus (HPC) were collected for post-
mortem receptor binding and Western blot analyses (n = 8 per group). CBD treatment attenuated poly I:C-
induced deficits in cannabinoid CB1 receptor binding in the PFC and glutamate decarboxylase 67, the
enzyme that converts glutamate to GABA, in the HPC. CBD treatment increased parvalbumin levels in the
HPC, regardless of whether offspring were exposed to poly I:C in utero. Conversely, CBD did not affect N-
methyl-d-aspartate receptor and gamma-aminobutyric acid (GABA) A receptor binding or protein levels of
fatty acid amide hydrolase, the enzyme that degrades the endocannabinoid, anandamide. Overall, these
findings show that CBD can restore cannabinoid/GABAergic signalling deficits in regions of the brain
implicated in schizophrenia pathophysiology following maternal poly I:C exposure. These findings provide
novel evidence for the potential mechanisms underlying the therapeutic effects of CBD treatment in the poly
I:C model.
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Abstract  51 
The mainstay treatment for schizophrenia is antipsychotic drugs (APDs), which are mostly 52 
effective against the positive symptoms (e.g. hallucinations), but provide minimal benefits for 53 
the negative symptoms (e.g. social withdrawal) and cognitive deficits. We have recently 54 
shown that treatment with the non-intoxicating phytocannabinoid, cannabidiol (CBD), can 55 
improve cognition and social interaction deficits in a maternal immune activation (MIA) 56 
model relevant to the aetiology of schizophrenia, however, the mechanisms underlying this 57 
effect are unknown. An imbalance in the main excitatory (glutamate) and inhibitory (GABA) 58 
neurotransmitter systems in the brain plays a role in the pathophysiology of schizophrenia. 59 
Therefore, the endocannabinoid system could represent a therapeutic target for schizophrenia 60 
as a regulator of glutamate and GABA release via the CB1 receptor (CB1R). This study 61 
investigated the effects of chronic CBD treatment on markers of glutamatergic, GABAergic 62 
and endocannabinoid signalling in brain regions implicated in social behaviour and cognitive 63 
function, including the prefrontal cortex (PFC) and hippocampus (HPC). Time-mated 64 
pregnant Sprague-Dawley rats (n = 16) were administered poly I:C (4 mg/kg, i.v.) or saline 65 
(control) on gestational day 15. Male offspring were injected with CBD (10 mg/kg, i.p.) or 66 
vehicle twice daily from postnatal day 56 for 3 weeks. The prefrontal cortex (PFC) and 67 
hippocampus (HPC) were collected for post-mortem receptor binding and Western blot 68 
analyses (n = 8 per group). CBD treatment attenuated poly I:C-induced deficits in 69 
cannabinoid CB1 receptor binding in the PFC and glutamate decarboxylase 67, the enzyme 70 
that converts glutamate to GABA, in the HPC. CBD treatment increased parvalbumin levels 71 
in the HPC, regardless of whether offspring were exposed to poly I:C in utero. Conversely, 72 
CBD did not affect N-methyl-D-aspartate receptor and gamma-aminobutyric acid (GABA) A 73 
receptor binding or protein levels of fatty acid amide hydrolase, the enzyme that degrades the 74 
endocannabinoid, anandamide. Overall, these findings show that CBD can restore 75 
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cannabinoid/GABAergic signalling deficits in regions of the brain implicated in 76 
schizophrenia pathophysiology following maternal poly I:C exposure. These findings provide 77 
novel evidence for the potential mechanisms underlying the therapeutic effects of CBD 78 
treatment in the poly I:C  model.   79 
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1. Introduction 80 
  81 
The prefrontal cortex (PFC) and hippocampus (HPC) are anatomically connected and 82 
synchrony between the two regions in important for normal brain function (Li et al., 2015). 83 
However, people with schizophrenia exhibit structural abnormalities in these brain regions, 84 
including reduced hippocampal volume and cortical thinning in the PFC (Dietsche et al., 85 
2017; van Erp et al., 2016). In addition, patients show abnormal activity in the default mode 86 
network (i.e. the network of brain regions that are active at rest) and during memory tasks 87 
(e.g. evidenced by reduced gamma oscillations), suggesting that dysfunction in these regions 88 
may underlie the symptomatology of the disorder, particularly the negative and cognitive 89 
symptom domains (Gonzalez-Burgos and Lewis, 2012; Guo et al., 2017). Unfortunately, the 90 
negative and cognitive symptoms tend to precede the onset of psychosis, are persistent over 91 
the course of the disorder, and are associated with poor functional outcomes in patients 92 
(Lindenmayer et al., 2013; Barch and Ceaser, 2012). Although antipsychotic drugs (APDs) 93 
are generally effective at controlling the positive symptoms of schizophrenia (e.g. 94 
hallucinations and delusions), the drugs have poor efficacy against the negative symptoms 95 
(e.g. social withdrawal) (Lindenmayer et al., 2013) and cognitive deficits of schizophrenia 96 
(Goff et al., 2011), and in some cases can worsen cognition (Hill et al., 2010). Despite the 97 
introduction of newer ‘second generation’ APDs to the market, this drug class does not 98 
exhibit superior efficacy to ‘first generation’ APDs (reviewed in MacKenzie et al., 2018). 99 
Therefore, new therapeutic options that can address the negative and cognitive symptom 100 
domains of schizophrenia are required. 101 
 102 
Cannabidiol (CBD), the main non-intoxicating phytocannabinoid found in the cannabis plant, 103 
has the potential to alleviate symptoms across a range of pathological conditions, including 104 
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epilepsy, chronic pain, anxiety and movement disorders (e.g. Parkinson’s disease) (Crippa et 105 
al., 2018; Osborne et al., 2017b). However, there are limited studies that have investigated the 106 
chronic effects of CBD treatment in schizophrenia. CBD (800 mg, 4 weeks) significantly 107 
improved symptoms (measured on the Positive and Negative Syndrome Scale (PANSS)) in 108 
acute paranoid schizophrenia patients in a manner comparable to amisulpride, but had a more 109 
favourable side effect profile (e.g. less body weight gain) (Leweke et al., 2012). Recent 110 
clinical trials have explored the therapeutic potential of CBD as an adjunct to existing APD 111 
medications of stable schizophrenia outpatients. After 6 weeks of treatment, PANSS scores of 112 
the CBD-treated group (1000 mg/day, 6 weeks) significantly improved compared to placebo, 113 
while cognition improved from baseline (assessed using Brief Assessment of Cognition in 114 
Schizophrenia), but fell short of statistical significance against placebo (p = 0.068) (McGuire 115 
et al., 2018). In contrast, a similar trial that used a lower dose of CBD (600 mg/day, 6 weeks) 116 
found no improvement on PANSS or the MATRICS Consensus Cognitive Battery compared 117 
to baseline (Boggs et al., 2018), suggesting that dosage may be a critical factor for the 118 
efficacy of CBD in schizophrenia, particularly in APD-treated patients. Our laboratory 119 
recently reported that CBD treatment improved cognition and social interaction in adult male 120 
rat offspring exposed to maternal immune activation (MIA) using polyinosinic-polycytidilic 121 
(poly I:C) acid (Osborne et al., 2017a), which mimics some of the positive and negative 122 
symptoms, and cognitive deficits observed in schizophrenia (Meyer and Feldon, 2012). 123 
However, the mechanisms by which CBD improves negative and cognitive phenotypes in 124 
poly I:C offspring is unknown.  125 
 126 
The endogenous cannabinoid (eCB) system plays an important role in various physiological 127 
functions, including neuroprotection, synaptic plasticity, memory and reward processing. The 128 
cannabinoid CB1 receptor (CB1R) is the main receptor of the eCB system in the brain with 129 
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high expression levels in regions involved in cognitive function, including the PFC and HPC 130 
(Lu and Mackie, 2016). Multiple studies have implicated eCB system dysregulation in the 131 
pathophysiology of schizophrenia, including alterations in CB1R expression (reviewed in 132 
Ferretjans et al., 2012), its endogenous ligand anandamide (AEA) (De Marchi et al., 2003; 133 
Giuffrida et al., 2004; Koethe et al., 2009; Leweke et al., 1999), and fatty acid amide 134 
hydrolase (FAAH), the enzyme primarily responsible for the degradation of AEA (Bioque et 135 
al., 2013; Takata et al., 2013). The eCB system is functionally linked to the major excitatory 136 
(glutamatergic) and inhibitory (GABAergic) neurotransmitter systems in the brain, as 137 
endogenous cannabinoids bind to the CB1R and dampen presynaptic glutamate and/or 138 
GABA release (Viveros et al., 2012). An imbalance in glutamatergic and GABAergic 139 
signalling in the brain has been implicated in the cognitive deficits of schizophrenia 140 
(Gonzalez-Burgos and Lewis, 2012). Post-mortem schizophrenia studies report alterations in 141 
the ionotropic glutamatergic N-methyl-D-aspartate receptor (NMDAR) and its obligatory 142 
GluN1 subunit (Catts et al., 2016), and gamma-aminobutyric acid alpha receptor (GABAAR) 143 
(Gonzalez-Burgos and Lewis, 2008), as well as a reduction in glutamate decarboxylase 67 144 
(GAD67; the rate-limiting enzyme that converts glutamate to GABA) and the calcium binding 145 
protein parvalbumin (PV), expressed on GABAergic interneurons (Cohen et al., 2015). The 146 
interaction of CBD with the eCB, glutamatergic and GABAergic systems is not well 147 
understood. CBD blocks the effects of CB1R/CB2 combined receptor agonists (McPartland 148 
et al., 2015; Pertwee, 2008; Thomas et al., 2007), acting as a CB1R negative allosteric 149 
modulator (NAM) in vitro (Laprairie et al., 2015) and may increase AEA levels by inhibiting 150 
FAAH activity (Leweke et al., 2012). Studies show that CBD can prevent behavioural and 151 
neurochemical deficits induced by NMDAR antagonism (Gomes et al., 2015a; Gururajan et 152 
al., 2012), and can act as a positive allosteric modulator of the GABAAR to increase 153 
inhibitory tone (Bakas et al., 2017). Therefore, the aim of this study was to examine the 154 
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effects of CBD treatment on eCB (CB1R binding density and FAAH protein levels), as well 155 
as glutamatergic (NMDAR binding and subunit levels) and GABAergic (GABAAR binding 156 
density, GAD67 and PV protein levels) markers in the brains of poly I:C offspring that exhibit 157 
cognitive deficits.  158 
 159 
 160 
2. Experimental Procedures 161 
 162 
2.1 Ethics Statement  163 
Experimental procedures were approved by the Animal Ethics Committee of the University 164 
of Wollongong, NSW, Australia (AE15/05) and complied with the National Health and 165 
Medical Research Council (NHMRC), Australian Code of Practice for the Care and Use of 166 
Animals for Scientific Purposes (NHMRC, 2013). All efforts were made to minimise the 167 
number and suffering of animals. 168 
 169 
2.2 Animal Experiments 170 
The detailed methods used for the animal experiments have been reported previously 171 
(Osborne et al., 2017a) in accordance with the Animal Research: Reporting of In Vivo 172 
Experiments (ARRIVE) guidelines (Kilkenny et al., 2010). Briefly, 16 time-mated pregnant 173 
Sprague-Dawley rats (12 weeks old, gestational day (GD) 15; Animal Resources Centre, 174 
Perth, WA) were administered poly I:C (4 mg/kg, i.v; Sigma-Aldrich, Castle Hill, Australia) 175 
or saline (control) to the lateral tail vein. Offspring were not cross-fostered and were 176 
maintained with their respective dams until weaning. After weaning (postnatal day (PN) 21), 177 
male offspring were pair-housed with same-treatment littermates. Offspring were 178 
administered CBD (10 mg/kg; i.p.; THC-Pharm GmbH, Frankfurt, Germany) dissolved in 179 
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Tween 80 and saline (vehicle, 1:16 (v/v); Chem Supply, Gillman, Australia), or vehicle 180 
(control), twice daily at 12 hourly intervals from PN 56 to PN 80, equating to late 181 
adolescence/early adulthood (Osborne et al., 2017a). The dose and duration of CBD 182 
administration was based on studies that report improvement in models with cognitive 183 
impairment following CBD treatment (Cassol et al., 2010; Barichello et al., 2012; Fagherazzi 184 
et al., 2012; Schiavon et al., 2014). During the second week of treatment (i.e. PN72), 185 
offspring underwent behavioural testing using the Novel Object Recognition, T-maze and 186 
Social Interaction tests as reported previously (Osborne et al., 2017a). The day after the last 187 
drug treatment, offspring were euthanased using carbon dioxide asphyxiation followed by 188 
rapid decapitation, between 09:00 and 11:30 h to minimise the potential effects of circadian 189 
rhythm variation on protein expression (Jasinska and Pyza, 2017). Whole brains were 190 
removed, immediately frozen in liquid nitrogen and stored at -80ºC until further analysis. 191 
 192 
2.3 Histological Procedures 193 
Rat brains (n = 8 per group) were sectioned coronally into alternating 14 µM or 500 µM 194 
sections using a cryostat (-17°C; Jung CM 3000, Leica Instruments GmbH, Nussloch, 195 
Germany). Sections were collected from the PFC (containing the prelimbic and infralimbic 196 
cortices; Bregma level: 4.2 mm to 2.56 mm) and HPC (containing the dorsal and ventral 197 
subregions, Bregma level: - 4.36 mm to - 6.00 mm). Consecutive sections (2-3 per region, per 198 
rat) were collected for receptor autoradiography experiments (14 µM) and thaw-mounted 199 
onto PolysineTM slides (Sigma-Aldrich, Castle Hill, NSW, Australia) then stored at -20ºC 200 
until further analysis. Sections (2-3 per region, per rat) collected for Western blot 201 
experiments (500 µM) were mounted on glass slides and regions of interest were 202 
microdissected using a micropuncture kit, then stored at -80ºC until further use. This 203 
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dissection protocol allowed investigation of receptor binding and protein levels from the 204 
same animals.  205 
 206 
2.4 In situ Receptor Autoradiography 207 
 208 
2.4.1 CB1R binding  209 
CB1R binding density was examined using in situ receptor autoradiography methods 210 
previously reported by our laboratory (Weston-Green et al., 2012a; Yu et al., 2013). Briefly, 211 
slides (3 slides per rat, per treatment group) were air-dried and incubated in 50 mM Tris-HCl 212 
buffer (pH 7.4) with 0.1% bovine serum albumin (BSA) for 15 min at room temperature. To 213 
determine total binding, sections were incubated in 50 mM Tris-HCl buffer (with 0.1% BSA) 214 
containing 10 nM [3H]SR141716A (43 Ci/mmol; PerkinElmer TM Life and Analytical 215 
Sciences, Boston, USA), a selective inverse agonist for the CB1R, for 60 min at room 216 
temperature. Non-specific binding was determined by incubating additional sections in 10 217 
nM [3H]SR141716A in the presence of 100 μM CP-55940 (Sapphire Bioscience, Redfern, 218 
NSW, Australia), a non-selective agonist of cannabinoid receptors. After incubation, slides 219 
were washed twice for 30 min in ice-cold buffer, rinsed in cold milliQ water and air-dried 220 
overnight.  221 
 222 
2.4.2 NMDAR binding  223 
NMDAR binding density was examined based on methods previously described by our 224 
laboratory (du Bois et al., 2009; Newell et al., 2007). Briefly, sections were incubated in 30 225 
mM N-2-hydroxyethyl piperazine-N′-2-ethanesulphonic acid (HEPES) buffer pH 7.5, 226 
containing 100 µM glycine, 100 µM glutamate, 1 mM ethylenediaminetetraacetic acid 227 
(EDTA) and 20 nM [3H]MK-801 (specific activity 22.5 Ci/mmol, PerkinElmer, Boston, 228 
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USA) for 2.5 hours at room temperature (RT). Non-specific binding was determined by 229 
incubating sections in the same buffer containing [3H]MK-801 in the presence of 200 µM 230 
unlabelled MK-801 (Sigma-Aldrich, Castle Hill, NSW, Australia). After incubation, sections 231 
were washed twice in ice-cold 30 mM HEPES buffer containing 1 mM EDTA (pH 7.5) for 232 
20 min each, rinsed in cold milliQ water and air-dried overnight. 233 
 234 
2.4.3 GABAAR binding  235 
GABAA receptor binding density was examined based on methods previously described by 236 
our laboratory and others (du Bois et al., 2009; Xia and Haddad, 1992; Yu et al., 2013). 237 
Briefly, sections were pre-incubated three times in 50 mM Tris-citrate (pH 7.0) buffer at 4ºC 238 
for 5 mins. Sections were incubated in 50 mM Tris-citrate buffer containing 50 nM [3H] 239 
muscimol (specific activity 29.5 Ci/mmol, PerkinElmer, Boston, USA), a selective agonist 240 
for the GABAAR, for 45 min at 4ºC. Non-specific binding was determined by incubating 241 
sections in 50 mM Tris-citrate (pH 7.0) buffer containing [3H] muscimol and 100 µM GABA 242 
(Sigma-Aldrich, Castle Hill, NSW, Australia). After incubation, sections were rinsed four 243 
times for 2 sec each in 50 mM Tris-citrate buffer (4°C), rinsed in cold milliQ water and air-244 
dried overnight.  245 
 246 
2.4.4 Quantification 247 
Slides from CB1R, NMDAR and GABAAR binding experiments were exposed to Amersham 248 
Hyperfilm ECL (GE Healthcare Life Sciences, Parramatta, NSW, Australia) for 5 (NMDAR 249 
and GABAAR) or 8 weeks (CB1R) with a set of Amersham tritium standards. After 250 
development, autoradiography films were de-identified, scanned using a GS-800 Imaging 251 
Densitometer (Bio-Rad, Hercules, California, USA), and quantified (left and right 252 
hemispheres) with Image J software (https://imagej.nih.gov/ij). Images were calibrated based 253 
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on the Rodbard curve obtained from the tritium standards to produce nCi/mg tissue 254 
equivalent (TE) values. Specific binding density was estimated by subtracting non-specific 255 
binding from total binding values. Values were converted to fmoles [3H] ligand per mg TE 256 
taking into account the specific activity of the ligand, as we have previously reported 257 
(Weston-Green et al., 2012a, 2012c, 2008). Tissue sections that were damaged were excluded 258 
from analysis. Anatomical structures were confirmed using a standard rat brain atlas (Paxinos 259 
and Watson, 2007).  260 
 261 
2.5 Western Blot and Quantification 262 
Brain samples containing the PFC and HPC (left and right hemispheres combined) were 263 
homogenised in buffer containing 0.1 M Tris-HCl, 2 mM EDTA, 10% glycerol, 2% SDS, 0.5 264 
mM PMSF, Protease Inhibitor Cocktail (P8340; Sigma-Aldrich, Australia) and Phosphatase 265 
Inhibitor Cocktail 2 (P5726; Sigma-Aldrich, Australia) as previously described (Lum et al., 266 
2016). A DC assay kit was used to determine total protein concentration following the 267 
manufacturer’s instructions (Bio-Rad, Australia). Crude homogenates (10 µg protein; within 268 
the linear range of detection of the primary antibodies, see Supplementary Figure 1) were 269 
loaded into CriterionTM TGX Stain-FreeTM 4-20% gels (Bio-Rad, Australia) and underwent 270 
electrophoresis in SDS buffer at 180V for 1 h. Gels were activated (GelDoc XR+ imaging 271 
system; Bio-Rad, Australia) (Colella et al., 2012; Gürtler et al., 2013), proteins were 272 
transferred on to polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Australia) via 273 
electrophoresis for 1 h at 100 V, and imaged (GelDoc XR+ imaging system; Bio-Rad, 274 
Australia) to capture total protein in each lane (Colella et al., 2012; Gürtler et al., 2013). 275 
Membranes were blocked in 5% milk (w/v) in Tris Buffered Saline with Tween 20® (TBST) 276 
for 1 h at room temperature. To detect the proteins of interest, membranes were incubated 277 
overnight at 4ºC in the following primary antibodies: anti-FAAH (PFC: 1:2500, HPC: 1:5000 278 
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; #ab54615, Abcam), anti-GluN1 (1:10 000; #MAB363, Millipore), anti-GAD67 (1:7500 279 
#MAB5406, Millipore), anti-PV (1:10 000; #Ab11427, Abcam). Membranes were washed in 280 
TBST (5 x 5 min) and incubated at room temperature for 1 h with either horseradish 281 
peroxidase (HRP)-conjugated goat anti-rabbit (1:5000; #AP307P, Millipore) or anti-mouse 282 
secondary antibody (1:5000; #AP308P, Millipore). After washing in TBST (3 x 5 min), 283 
membranes were incubated in Enhanced Chemiluminescence (ECL) reagents (Bio-strategy 284 
Laboratory Products, Tingalpa, QLD Australia) and scanned using a Gel Imager (Amersham 285 
600RB, GE Healthcare, Parramatta, NSW Australia). De-identified band signals were 286 
quantified using Image Lab software (ver 6, Bio-Rad Laboratories Inc, California, USA). The 287 
values for each signal were normalised to total protein in the respective lane to account for 288 
loading variability (Colella et al., 2012; Gürtler et al., 2013). Values were then normalised to 289 
an internal control sample (consisting of equal amounts of sample pooled together) to account 290 
for inter-gel variability. Samples were assayed in duplicate at a minimum.  291 
 292 
2.6 Statistical Analysis 293 
Statistical analyses were performed using SPSS (Version 21.0, IBM Inc., Illinois, USA). Data 294 
points that were ± 2SD from the mean were considered outliers and removed from analysis. 295 
Data were tested for normality using Shapiro-Wilk tests. Two-way ANOVAs were used to 296 
examine the effects of PRENATAL INFECTION (poly I:C vs. vehicle) and OFFSPRING 297 
TREATMENT (CBD vs. vehicle) on receptor binding density and protein levels. Pairwise 298 
comparisons (with Bonferroni adjustment) were used to examine differences between groups. 299 
Data that were not normally distributed were transformed, retested for normality using 300 
Shapiro-Wilk tests, and analysed using parametric testing. Variables that remained non-301 
normally distributed following transformation or that violated Levene’s Test for Equality of 302 
Variances were analysed using non-parametric Mann-Whitney U tests (indicated in the 303 
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Results section). Relevant comparisons were made between vehicle-treated control and poly 304 
I:C offspring (CONT+VEH vs. POLY+VEH), vehicle and CBD-treated poly I:C offspring 305 
(POLY+VEH vs. POLY+CBD), as well as vehicle and CBD-treated control offspring 306 
(CONT+VEH vs. CONT+CBD). Where significant differences between the POLY+VEH and 307 
POLY+CBD groups were observed, an additional comparison was made between the 308 
CONT+VEH and POLY+CBD groups to determine if CBD restored the parameter to control 309 
levels. P values less than 0.05 were considered statistically significant. Data are presented as 310 
mean ± standard error of the mean (SEM).  311 
 312 
 313 
3. Results 314 
To determine the potential mechanisms underlying the beneficial effects of CBD, eCB, 315 
NMDAR and GABAergic markers were analysed in the brains of control and poly I:C 316 
offspring. Representative autoradiographs of CB1R ([3H]SR141716A), NMDAR ([3H]MK-317 
801) and GABAAR ([3H]Muscimol) total binding density (as well as non-specific binding for 318 
the respective ligands) in the PFC and HPC are shown (Figure 1). There was no difference in 319 
receptor binding density along the dorsal-ventral axis of the HPC (Supplementary Figure 2); 320 
therefore, the subregions were combined for analysis. Representative immunoblots showing 321 
the expected bands for FAAH (Figure 2C, 2D), the obligatory GluN1 subunit of the NMDAR 322 
(Figure 3C, 3D), GAD67 (Figure 4C, 4D) and PV (Figure 4E, 4F) are displayed with their 323 



















Figure 1: Example autoradiographs showing cannabinoid CB1 receptor (CB1R), N-methyl-341 
D-aspartate receptor (NMDAR) and gamma-aminobutyric acid A receptor (GABAAR) 342 
binding in the adult rat brain. Schematic diagram adapted from a rat brain atlas (Paxinos and 343 
Watson, 2007) showing the approximate Bregma level quantified for the prefrontal cortex 344 
(PFC): 2.52 mm (containing the prelimbic and infralimbic cortices; shaded) and the 345 
hippocampus (HPC): - 4.92 mm (shaded). Example autoradiographs demonstrate 346 
[3H]SR141716A binding to CB1Rs, [3H]MK-801 binding to NMDARs and [3H]muscimol 347 
binding to GABAARs in the PFC and HPC. Autoradiographs show total binding (left) and 348 
non-specific binding (right) for each ligand. Example autoradiographs are from vehicle-349 
treated control offspring.  350 
 351 
 352 
3.1 Effect of cannabidiol on endocannabinoid markers 353 
CB1R binding density and FAAH protein levels were examined in the PFC and HPC to 354 
determine if maternal poly I:C exposure could result in persistent alterations to eCB markers, 355 




significant main effect of OFFSPRING TREATMENT (F (1, 26) = 6.481, p = 0.017) and a 357 
tendency for a PRENATAL INFECTION x OFFSPRING TREATMENT interaction (F (1, 26) 358 
= 2.993, p = 0.095), but no main effect of PRENATAL INFECTION (F (1, 26) = 1.679, p = 359 
0.206). Although the interaction did not reach statistical significance, visual inspection of the 360 
graph showed that poly I:C offspring had lower CB1R binding density in the PFC compared 361 
to control counterparts (-24.62%; POLY+VEH vs. CONT+VEH, p = 0.042) (Figure 2A). 362 
CBD treatment restored CB1R binding deficits in poly I:C offspring (+46.16%; POLY+CBD 363 
vs. POLY+VEH, p = 0.006) to control-like levels (POLY+CBD: 247.85 ± 15.19 vs. 364 
CONT+VEH: 224.97 ± 13.03; p = 0.275) (Figure 2A). CBD administration did not 365 
significantly alter CB1R binding density in the PFC of control offspring (CONT+CBD: 366 
239.91 ± 19.92 vs. CONT+VEH: 224.97 ± 13.03; p = 0.569) (Figure 2A). The reduction in 367 
CB1R binding density in poly I:C offspring appeared to be specific to the PFC, since there 368 
were no significant effects of maternal poly I:C exposure or CBD treatment on CB1R binding 369 
density in the HPC of offspring (PRENATAL INFECTION: F (1, 23) = 0.326, p = 0.574; 370 
OFFSPRING TREATMENT: F (1, 23) = 0.790, p = 0.383; PRENATAL INFECTION x 371 
OFFSPRING TREATMENT: F (1, 23) = 0.321, p = 0.576) (Figure 2B). FAAH protein levels 372 
in the PFC did not differ significantly between treatment groups (PRENATAL INFECTION: 373 
F (1, 27) = 0.112, p = 0.740; OFFSPRING TREATMENT: F (1, 27) = 1.610, p = 0.215; 374 
PRENATAL INFECTION x OFFSPRING TREATMENT: F (1, 27) = 0.690, p = 0.413) 375 
(Figure 2C). In line with the findings in the PFC, a two-way ANOVA showed no significant 376 
effects on FAAH protein levels in the HPC (PRENATAL INFECTION: F (1, 28) = 0.066, p = 377 
0.800, OFFSPRING TREATMENT: F (1, 28) = 0.356, p = 0.556, PRENATAL INFECTION x 378 





















Figure 2: Cannabidiol (CBD) attenuated deficits in cannabinoid CB1R binding density in the 398 
prefrontal cortex (PFC) of male offspring exposed to maternal poly I:C infection. CB1R 399 
([3H]SR141716A) binding density in the (A) PFC and (B) hippocampus (HPC) of offspring 400 
treatment groups. Normalised fatty acid amide hydrolase (FAAH) protein levels in the (C) 401 
PFC and (D) HPC with typical immunoblots for each treatment group shown underneath the 402 
graphs (normalised to total protein levels in the respective lanes). Data expressed as mean ± 403 
SEM. n = 6-8 rats per group. *p<0.05 vs. CONT+VEH, #p<0.05 vs. POLY+VEH group. TE 404 
= tissue equivalent.  405 



























































































































3.2 Effect of cannabidiol on the glutamatergic NMDAR 407 
The effect of CBD treatment on NMDAR binding density and the obligatory GluN1 subunit 408 
of the NMDAR were examined in the PFC and HPC of offspring. A two-way ANOVA 409 
showed no significant effects of PRENATAL INFECTION (F (1, 25) = 0.054, p = 0.818) or 410 
OFFSPRING TREATMENT (F (1, 25) = 0.430, p = 0.518) on NMDAR binding density in the 411 
PFC, and no significant interaction between the factors (F (1, 25) = 0.224, p = 0.640) (Figure 412 
3A). A similar pattern was also observed in the HPC (PRENATAL INFECTION: F (1, 23) = 413 
0.120, p = 0.732; OFFSPRING TREATMENT: F (1, 23) = 2.256, p = 0.147; PRENATAL 414 
INFECTION x OFFSPRING TREATMENT: F (1, 23) = 0.712, p = 0.408) (Figure 3B). 415 
Reflecting the lack of change in binding density, GluN1 protein levels were not significantly 416 
altered between treatment groups in the PFC (Figure 3C) or HPC (Figure 3D) (PFC: 417 
PRENATAL INFECTION: F (1, 27) = 0.045, p = 0.833; OFFSPRING TREATMENT: F (1, 27) 418 
= 1.763, p = 0.195; PRENATAL INFECTION x OFFSPRING TREATMENT: F (1, 27) = 419 
1.524, p = 0.228. HPC (Mann-Whitney U tests): POLY+VEH vs. CONT+VEH, p = 0.600; 420 





















Figure 3: Cannabidiol (CBD) did not alter glutamatergic N-methyl-D-aspartate receptor 440 
(NMDAR) binding density or GluN1 protein levels in select brain regions of control (CONT) 441 
and poly I:C (POLY) offspring. NMDAR ([3H]MK801) binding density in the (A) PFC and 442 
(B) HPC of offspring. Normalised GluN1 subunit protein levels (normalised to total protein 443 
levels in the respective lane) in the (C) PFC and (D) HPC, with typical GluN1 immunoblots 444 
(~105 kDa) shown underneath each graph. Data expressed as mean ± SEM. n = 6-8 rats per 445 






















































































































3.3 Effect of cannabidiol on GABAergic markers 450 
GABAAR binding density, as well as GAD67 and PV protein levels were examined in the 451 
PFC and HPC to determine whether CBD treatment could attenuate any changes in 452 
GABAergic markers following maternal poly I:C exposure. Mann-Whitney U tests revealed 453 
that poly I:C exposure did not significantly alter GABAAR binding density in the PFC 454 
(POLY+VEH vs. CONT+VEH: p = 0.568), and there was no significant impact of CBD 455 
treatment on GABAAR binding density in poly I:C (POLY+CBD vs. POLY+VEH: p = 456 
0.668) or control offspring (CONT+CBD vs. CONT+VEH: p = 0.317) (Figure 4A). 457 
Similarly, no significant changes in GABAAR binding density were observed in the HPC 458 
(PRENATAL INFECTION: F (1, 22) = 0.382, p = 0.543; OFFSPRING TREATMENT: F (1, 22) 459 
= 1.186, p = 0.288; PRENATAL INFECTION x OFFSPRING TREATMENT: F (1, 22) = 460 
1.814, p = 0.192) (Figure 4B). In the PFC, there was no significant difference in GAD67 461 
protein levels between groups (PRENATAL INFECTION: F (1, 28) = 0.244, p = 0.625; 462 
OFFSPRING TREATMENT: F (1, 28) = 0.149, p = 0.703; PRENATAL INFECTION x 463 
OFFSPRING TREATMENT: F (1, 28) = 0.364, p = 0.551) (Figure 4C). Conversely, a two-way 464 
ANOVA revealed significant main effects of PRENATAL INFECTION (F (1, 27) = 5.987, p = 465 
0.021) and OFFSPRING TREATMENT (F (1, 27) = 9.253, p = 0.005) on relative GAD67 466 
protein levels in the HPC. There was no significant PRENATAL INFECTION x 467 
OFFSPRING TREATMENT interaction (F (1, 27) = 0.600, p = 0.445); however, visual 468 
inspection of the means suggested individual group differences. Exploratory pairwise 469 
comparisons showed a significant reduction in GAD67 protein levels in poly I:C offspring (-470 
15.50%; POLY+VEH vs. CONT+VEH, p = 0.028), that was attenuated by CBD treatment 471 
(+17.85%; POLY+CBD vs. POLY+VEH, p = 0.013), and did not differ from controls 472 
(POLY+CBD: 1.04 ±0.05 vs. CONT+VEH: 1.01±0.05, p = 0.108) (Figure 4D). In the PFC, 473 
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Mann-Whitney tests showed no significant difference in PV protein levels between groups 474 
(CONT+VEH vs. CONT+CBD, p = 0.208; CONT+VEH vs. POLY+VEH, p = 0.247; 475 
POLY+VEH vs. POLY+CBD, p = 0.180) (Figure 4E). In the HPC however, CBD treatment 476 
significantly increased PV protein levels (+21.09 %, OFFSPRING TREATMENT: F (1, 26) = 477 
8.610, p = 0.007) relative to vehicle treatment (CBD: 1.04±0.05 vs. VEH: 0.82±0.06) (Figure 478 
4F). There was no main effect of PRENATAL INFECTION (F (1, 26) = 0.314, p = 0.580) and 479 











































Figure 4: Cannabidiol (CBD) treatment altered glutamate decarboxylase 67 (GAD67) and 521 
pavalbumin (PV) protein levels in the hippocampus (HPC) of control (CONT) and poly I:C 522 
(POLY) offspring. GABAAR ([3H]Muscimol) binding density in the (A) prefrontal cortex 523 











































































































































































(~67 kDa)  
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(GAD67) (C, D) and parvalbumin (PV) (E, F) protein levels (normalised to total protein 525 
levels in the respective lanes) in the PFC and HPC with representative immunoblots shown 526 
underneath the graphs. *p < 0.05 vs. CONT+VEH group, #p < 0.05 vs. POLY+VEH group; 527 
lines indicate offspring treatment effect (p < 0.01 CBD vs. VEH). Data expressed as mean ± 528 
SEM. n = 6-8 rats per group.  529 
 530 
 531 
4. Discussion 532 
 533 
We have previously shown that CBD treatment restored working and recognition memory, as 534 
well as social interaction deficits in male poly I:C offspring (Osborne et al., 2017a), however, 535 
the effects of CBD treatment on brain neurochemistry had not been characterised. The 536 
present study examined the effect of CBD treatment on eCB, glutamatergic and GABAergic 537 
markers in the PFC and HPC of male poly I:C offspring. We have shown that CBD treatment 538 
restored poly I:C-induced deficits in CB1R binding density in the PFC and hippocampal 539 
GAD67 levels, and increased PV protein levels in the HPC regardless of whether offspring 540 
were exposed to poly I:C in utero. This study provides the first evidence for the potential 541 
molecular mechanisms underlying the therapeutic effects of CBD in the poly I:C model, and 542 
may have implications for schizophrenia treatment.  543 
 544 
In the present study, we found that CB1R binding density was reduced in the PFC, but not the 545 
HPC of male poly I:C offspring that exhibit social interaction, recognition and working 546 
memory deficits (Osborne et al., 2017a). In line with our findings, post-mortem studies of 547 
predominantly male schizophrenia cohorts report alterations in CB1R expression in the PFC 548 
(Eggan et al., 2010, 2008; Urigüen et al., 2009), but not the HPC (Dean et al., 2001). 549 
Similarly, in other neurodevelopmental rodent models of schizophrenia, studies report 550 
alterations in CB1R protein and mRNA expression in the PFC following gestational 551 
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methylazoxymethanol (MAM) administration (Stark  et al., 2019; Gomes et al., 2018), with 552 
no change in CB1R binding, protein or mRNA expression in the HPC of male 553 
lipopolysaccharide- or MAM-exposed (in utero) offspring (Stark et al., 2019; Gomes et al., 554 
2018; Zavitsanou et al., 2013). However, this is the first study to report a corresponding 555 
reduction in CB1R binding density in the PFC, a region critical to memory and social 556 
behaviour, in male poly I:C offspring that also exhibit negative and cognitive phenotypes. 557 
Our findings are similar to a recent study that reported social interaction and recognition 558 
memory deficits in male offspring following gestational methylazoxymethanol (MAM) 559 
exposure, with concurrent alterations in CB1R protein and mRNA expression (albeit 560 
increases) in the PFC, but not the HPC of male offspring (Stark et al., 2019). It is unknown 561 
how CBD rescues changes in CB1R expression in neurodevelopmental models. Recent in 562 
vitro evidence suggests that CBD has an alternative mechanism of action to other 563 
phytocannabinoids (e.g. THC), instead acting as a negative allosteric modulator of the CB1R 564 
(Laprairie et al., 2015; Straiker et al., 2018; Tham et al., 2018). However, whether negative 565 
allosteric modulation of the CB1R by CBD is responsible for the therapeutic effects observed 566 
in the present study and others (e.g. Stark et al., 2019) is yet to be elucidated.  567 
 568 
Deficits in GABAergic signalling are thought to underlie the pathophysiology of 569 
schizophrenia, with post-mortem studies consistently reporting a reduction in GAD67 and PV 570 
expression in the cortex and HPC of patients (Guidotti et al., 2000; Zhang et al., 2002; 571 
Thompson et al., 2011; Kimoto et al., 2014). The reduction in hippocampal GAD67 levels 572 
observed in the present study aligns with previous poly I:C studies that report reduced GAD67 573 
protein and mRNA expression, mainly in the dorsal HPC (Dickerson et al., 2014; Luoni et al., 574 
2017; Richetto et al., 2013), with no changes in the medial PFC (Dickerson et al., 2014). 575 
Conversely, this is the first study to show that CBD can reverse deficits in hippocampal 576 
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GAD67 protein levels in poly I:C offspring. GAD67 is the rate-limiting enzyme responsible for 577 
approximately 90% of GABA synthesis in the brain and can provide an indication of GABA 578 
levels (Lazarus et al., 2015). Indeed, previous in vitro studies have reported that CBD can 579 
elevate GABA levels in cortical (Banerjee et al., 1975) and striatal membranes (Sagredo et 580 
al., 2007) by inhibiting GABA reuptake. While not impaired in poly I:C offspring in the 581 
present study, PV protein levels in the HPC were significantly increased by CBD treatment. 582 
The effect of CBD on hippocampal PV+ interneurons has not been reported in maternal 583 
manipulation models of schizophrenia previously; however, CBD attenuated a reduction in 584 
PV+ cells in the medial PFC following chronic administration of the NMDAR antagonist 585 
MK-801 (Gomes et al., 2015a). Importantly, PV expression is activity-dependent, therefore, 586 
taken together with recent in vitro findings that CBD can enhance inhibition elicited by PV+ 587 
and CCK+ GABAergic neurons (Khan et al., 2018), the results of the present study suggest 588 
that CBD may increase inhibitory tone within the hippocampus.  589 
 590 
In the present study, CBD treatment did not alter FAAH protein levels in the PFC or HPC. 591 
FAAH is the primary enzyme responsible for the intracellular hydrolysis of AEA in neurons 592 
(Lu and Mackie, 2016). AEA may play a protective role in schizophrenia, especially in the 593 
early stages of the disorder (Giuffrida et al., 2004; Koethe et al., 2009); therefore, compounds 594 
that limit AEA degradation (e.g. FAAH inhibitors) may be beneficial. Previous in vitro 595 
investigations have identified CBD as a FAAH inhibitor (Elmes et al., 2015; Leweke et al., 596 
2012; Bisogno et al., 2001; De Petrocellis et al., 2011). Although we did not detect any 597 
changes in FAAH protein levels following CBD treatment in the present study, we cannot 598 
discount changes in enzymatic activity. Alternatively, CBD could interact with fatty acid 599 
binding proteins, which are responsible for transporting AEA across the membrane for 600 
intracellular hydrolysis by FAAH (Elmes et al., 2015). Further examination of AEA transport 601 
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and degradation may provide additional insight into the mechanisms underlying the 602 
therapeutic benefits of CBD in the poly I:C model.  603 
 604 
CBD treatment did not alter NMDAR (or protein levels of its obligatory GluN1 subunit) and 605 
GABAAR binding, which are primarily responsible for excitation and inhibition in the mature 606 
brain, respectively. Our findings contrast with post-mortem studies in schizophrenia patients 607 
that report a modest down-regulation in NMDAR binding (Catts et al., 2016), with a 608 
corresponding up-regulation in GABAAR binding density (Benes et al., 1996a, 1996b; 609 
Verdurand et al., 2013). Alterations in individual receptor subunits have also been reported, 610 
including down-regulation of the GluN1 subunit of the NMDAR (Catts et al., 2015; Weickert 611 
et al., 2013), as well as specific α subunits of the GABAAR in patients (Beneyto et al., 2011; 612 
Volk et al., 2002) and poly I:C offspring (Meyer et al., 2008; Richetto et al., 2014). This is 613 
the first study to report that CBD treatment does not alter NMDAR and GABAAR binding 614 
density in male poly I:C offspring that do not exhibit binding deficits in these receptors. 615 
Literature investigating the effects of CBD treatment on these neurochemical markers in 616 
other preclinical schizophrenia models is limited. In line with the present study, CBD did not 617 
alter NMDAR or GABAAR density in a genetic mouse model of schizophrenia-like 618 
phenotypes (Neuregulin 1 transmembrane domain heterozygous mutant mice) that did not 619 
exhibit binding deficits (Long et al., 2012), but did restore GluN1 gene expression in the PFC 620 
of rodents exposed to NMDAR antagonism (MK-801) (Gomes et al., 2015a). Overall, the 621 
findings of the present study suggest that CBD may not exert its therapeutic effects via the 622 
NMDAR and GABAARs in poly I:C offspring. However, we cannot discount changes in 623 
other subunits of the NMDAR (e.g. GluN2A or GluN2B) or GABAAR (e.g. α subunits). 624 
Alternatively, CBD could alter receptor activity or expression on specific neuronal 625 
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populations (e.g. PV+ interneurons, pyramidal cells) not detectable in the present study, 626 
which could be addressed by future investigations.  627 
 628 
Although further research is needed to characterise the neurochemical changes observed 629 
following CBD treatment, this study provides the first insight into the potential mechanisms 630 
underlying the beneficial effects of CBD in a MIA model of schizophrenia. Following on 631 
from the previous behavioural investigation (Osborne et al., 2017a), the present study is 632 
limited by the use male offspring only. The eCB system is known to exhibit sexual 633 
dimorphism, particularly in CB1R expression and functionality (Rubino and Parolaro, 2011), 634 
therefore, future studies are needed to determine if female poly I:C offspring show a similar 635 
response to CBD treatment. Additionally, it is unclear whether the downregulation in CB1R 636 
binding and GAD67 levels in poly I:C offspring are a delayed result of the poly I:C stimulus; 637 
GABAergic and eCB signalling is present in the brain from early prenatal development 638 
(Danglot et al., 2006; Harkany et al., 2007), playing an important role in neuronal migration 639 
and proliferation, and is vulnerable to neuroinflammation (Di Marzo et al., 2015). Given that 640 
some behavioural phenotypes show delayed onset in the poly I:C model (reviewed in Meyer 641 
and Feldon, 2012), tracking the neurochemical profile of offspring would elucidate whether 642 
the deficits in CB1R binding and GAD67 levels are present from gestation (i.e. after the 643 
immune stimulus is delivered), or if the poly I:C insult primes the brain for altered maturation 644 
during adolescence. Nevertheless, CBD treatment during adolescence/early adulthood was 645 
able to rectify the behavioural (Osborne et al., 2017a) and neurochemical deficits observed in 646 







In the present study, CBD treatment reversed deficits in CB1R binding density in the PFC 652 
and hippocampal GAD67 protein levels in male poly I:C offspring. CBD also increased 653 
hippocampal PV levels regardless of in utero poly I:C exposure. CBD had no effect on 654 
FAAH protein levels, NMDAR or GABAAR binding density in either brain region examined, 655 
however, poly I:C offspring did not exhibit deficits in these markers. This is the first study to 656 
characterise the neurochemical changes that occur following CBD treatment in a MIA model 657 
of schizophrenia. Overall, our findings implicate eCB and GABAergic signalling markers in 658 
the therapeutic effects of CBD in male poly I:C offspring, and this may have important 659 
implications for schizophrenia treatment.  660 
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Supplementary Figure 1: Crude rat brain homogenate was prepared at increasing 1097 
concentrations of total protein (2.5, 5, 10, 15, 20 and 30 μg) and immunoblotted for the 1098 
primary antibodies of interest, A, B) fatty acid amide hydrolase (FAAH), C) GluN1 subunit, 1099 
D) glutamate decarboxylase (GAD67) and E) parvalbumin (PV), as previously described in 1100 




































































































Supplementary Figure 2: No difference in (A) CB1R ([3H]SR141716A), (B) NMDAR 1121 
([3H]MK801) or (C) GABAAR ([3H]Muscimol) binding density in the dorsal (left) and 1122 
ventral (right) hippocampus of control (CONT) and poly I:C (POLY) offspring. Data 1123 
expressed as mean ± SEM. n = 5-7 rats per group.  1124 
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